Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative.

Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT.

J Neuropathol Exp Neurol. 2002 Sep;61(9):797-805.

PMID:
12230326
2.

Targeting alzheimer amyloid plaques in vivo.

Wengenack TM, Curran GL, Poduslo JF.

Nat Biotechnol. 2000 Aug;18(8):868-72.

PMID:
10932157
3.

Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease.

Robbins EM, Betensky RA, Domnitz SB, Purcell SM, Garcia-Alloza M, Greenberg C, Rebeck GW, Hyman BT, Greenberg SM, Frosch MP, Bacskai BJ.

J Neurosci. 2006 Jan 11;26(2):365-71.

4.

Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.

Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF.

J Pharmacol Exp Ther. 2007 Aug;322(2):541-9. Epub 2007 May 15.

5.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076
6.

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.

Güntert A, Döbeli H, Bohrmann B.

Neuroscience. 2006 Dec 1;143(2):461-75. Epub 2006 Sep 27.

PMID:
17008022
7.

Aurones serve as probes of beta-amyloid plaques in Alzheimer's disease.

Ono M, Maya Y, Haratake M, Ito K, Mori H, Nakayama M.

Biochem Biophys Res Commun. 2007 Sep 14;361(1):116-21. Epub 2007 Jul 10.

PMID:
17644062
8.

Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain.

Shin RW, Ogino K, Kondo A, Saido TC, Trojanowski JQ, Kitamoto T, Tateishi J.

J Neurosci. 1997 Nov 1;17(21):8187-93.

9.

Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.

Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, Mathis CA, Klunk WE, Hyman BT.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12462-7. Epub 2003 Sep 29.

10.

Amyloid binding ligands as Alzheimer's disease therapies.

Lee VM.

Neurobiol Aging. 2002 Nov-Dec;23(6):1039-42. Review.

PMID:
12470800
11.

A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain.

Okamura N, Suemoto T, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Arai H, Sasaki H, Yanai K, Staufenbiel M, Kudo Y, Sawada T.

J Mol Neurosci. 2004;24(2):247-55.

PMID:
15456938
12.

Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.

Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF.

Brain Res. 2004 Oct 29;1025(1-2):98-105. Erratum in: Brain Res. 2005 Jan 21;1031(2):302.

PMID:
15464749
13.

Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM.

J Neurosci. 2005 Mar 16;25(11):2803-10.

14.

Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.

Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM.

J Cereb Blood Flow Metab. 2002 Feb;22(2):223-31.

PMID:
11823720
15.

IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques.

Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VM, Kung HF.

Brain Res. 2002 Nov 29;956(2):202-10.

PMID:
12445687
16.

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.

J Neurosci. 2005 Nov 16;25(46):10598-606.

17.

Binding of proteases to fibrillar amyloid-beta protein and its inhibition by Congo red.

Chander H, Chauhan A, Chauhan V.

J Alzheimers Dis. 2007 Nov;12(3):261-9.

PMID:
18057560
18.

Targeting prion amyloid deposits in vivo.

Sadowski M, Pankiewicz J, Scholtzova H, Tsai J, Li Y, Carp RI, Meeker HC, Gambetti P, Debnath M, Mathis CA, Shao L, Gan WB, Klunk WE, Wisniewski T.

J Neuropathol Exp Neurol. 2004 Jul;63(7):775-84.

PMID:
15290902
19.

Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains.

Ono M, Kawashima H, Nonaka A, Kawai T, Haratake M, Mori H, Kung MP, Kung HF, Saji H, Nakayama M.

J Med Chem. 2006 May 4;49(9):2725-30.

PMID:
16640332
20.

Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain.

Mathis CA, Wang Y, Klunk WE.

Curr Pharm Des. 2004;10(13):1469-92. Review.

PMID:
15134570

Supplemental Content

Support Center